Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Single Arm Study of Adebrelimab Combined with Apatinib and Gemcitabine and Cisplatin (GP) First-line Treatment for Unresectable Biliary Tract Carcinoma

NCT06749730 is registered in ClinicalTrials.gov with Henan Cancer Hospital as lead sponsor.

NCT NCT06749730
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06749730 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Single Arm Study of Adebrelimab Combined with Apatinib and Gemcitabine and Cisplatin (GP) First-line Treatment for Unresectable Biliary Tract Carcinoma
Lead sponsor
Henan Cancer Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
April 1, 2024
Completion date
June 30, 2027
Enrollment
63 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

unresectable biliary tract carcinoma